S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
Nucor Stock Should Be on Your Buying List
Are You Prepared for a Major Medical Crisis? Here's How a Crisis Can Affect You Financially
3 No-Brainer Stocks to Buy in the Financial Sector
Bitcoin-mining power plant raises ire of environmentalists
pixel
Unhappy with prices, ranchers look to build own meat plants
Learn Everything You Need to Know About Microsoft Windows 11 Before Launch
Backlog in federal safety rules amid US car crash ‘epidemic’
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
Nucor Stock Should Be on Your Buying List
Are You Prepared for a Major Medical Crisis? Here's How a Crisis Can Affect You Financially
3 No-Brainer Stocks to Buy in the Financial Sector
Bitcoin-mining power plant raises ire of environmentalists
pixel
Unhappy with prices, ranchers look to build own meat plants
Learn Everything You Need to Know About Microsoft Windows 11 Before Launch
Backlog in federal safety rules amid US car crash ‘epidemic’
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
Nucor Stock Should Be on Your Buying List
Are You Prepared for a Major Medical Crisis? Here's How a Crisis Can Affect You Financially
3 No-Brainer Stocks to Buy in the Financial Sector
Bitcoin-mining power plant raises ire of environmentalists
pixel
Unhappy with prices, ranchers look to build own meat plants
Learn Everything You Need to Know About Microsoft Windows 11 Before Launch
Backlog in federal safety rules amid US car crash ‘epidemic’
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
Nucor Stock Should Be on Your Buying List
Are You Prepared for a Major Medical Crisis? Here's How a Crisis Can Affect You Financially
3 No-Brainer Stocks to Buy in the Financial Sector
Bitcoin-mining power plant raises ire of environmentalists
pixel
Unhappy with prices, ranchers look to build own meat plants
Learn Everything You Need to Know About Microsoft Windows 11 Before Launch
Backlog in federal safety rules amid US car crash ‘epidemic’
pixel
NASDAQ:PTX

Pernix Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.03
▼
$0.21
52-Week Range N/A
Volume16,105 shs
Average Volume3.04 million shs
Market Capitalization$419,000.00
P/E RatioN/A
Dividend YieldN/A
Beta1.2

Receive PTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Pernix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Pernix Therapeutics logo

About Pernix Therapeutics

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.

Headlines

Pernix Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
May 26, 2020 |  www.bloomberg.com
Could The Platinex Inc. (CNSX:PTX) Ownership Structure Tell Us Something Useful?
May 3, 2020 |  finance.yahoo.com
Pernix Therapeutics Reports First Quarter 2017 Financial Results and Provides Business Update
February 16, 2020 |  www.bloomberg.com
Edited Transcript of PTX earnings conference call or presentation 7-Nov-17 9:30pm GMT
December 14, 2019 |  finance.yahoo.com
Bargain hunters drive Pernix up 47% - Seeking Alpha
February 23, 2019 |  seekingalpha.com
Pernix Therapeutics Holdings, Inc. Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management
February 19, 2019 |  www.marketwatch.com
Pernix files for bankruptcy; shares down 65%
February 19, 2019 |  seekingalpha.com
Pernix Therapeutics Holdings Inc
February 18, 2019 |  www.bloomberg.com
Could The Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) Ownership Structure Tell Us Something Useful?
February 16, 2019 |  finance.yahoo.com
Pernix Therapeutics: It Seems A Serious Sell
February 15, 2019 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PTX
Previous Symbol
CUSIP
71426V10
CIK
1024126
Web
www.pernixtx.com
Phone
800-793-2145
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$146.07 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($14.77) per share
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
$-77.14 million
Net Margins
-59.70%
Return on Equity
N/A
Return on Assets
-37.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.08
Quick Ratio
0.92

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
14,510,000
Market Cap
$419,000.00
Next Earnings Date
N/A
Optionable
Optionable

MarketRank™

Overall MarketRank™

0.99 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Pernix Therapeutics (NASDAQ:PTX) Frequently Asked Questions

What stocks does MarketBeat like better than Pernix Therapeutics?

Wall Street analysts have given Pernix Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pernix Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Pernix Therapeutics' key executives?

Pernix Therapeutics' management team includes the following people:
  • Mr. John Anthony Sedor, Chairman & CEO (Age 74)
  • Mr. Kenneth R. Pina Esq., Sr. VP, Chief Legal & Compliance Officer and Corp. Sec. (Age 60)
  • Mr. Glenn Whaley, VP of Fin., Principal Financial & Accounting Officer (Age 51)
  • Mr. Anthony M. Orrico, VP of Technical & Supply Operations
  • Mr. George P. Jones, VP of Sales & Marketing

What other stocks do shareholders of Pernix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pernix Therapeutics investors own include PIMCO High Income Fund (PHK), Synergy Pharmaceuticals (SGYP), Investors Bancorp (ISBC), Novavax (NVAX), Gevo (GEVO), Amira Nature Foods (ANFI), Argos Therapeutics (ARGSQ), Catalyst Pharmaceuticals (CPRX), (GBSN) (GBSN) and (FPP) (FPP).

What is Pernix Therapeutics' stock symbol?

Pernix Therapeutics trades on the NASDAQ under the ticker symbol "PTX."

How much money does Pernix Therapeutics make?

Pernix Therapeutics has a market capitalization of $0.00 and generates $146.07 million in revenue each year.

What is Pernix Therapeutics' official website?

The official website for Pernix Therapeutics is www.pernixtx.com.

Where are Pernix Therapeutics' headquarters?

Pernix Therapeutics is headquartered at 10 NORTH PARK PLACE SUITE 201, MORRISTOWN NJ, 07960.

How can I contact Pernix Therapeutics?

Pernix Therapeutics' mailing address is 10 NORTH PARK PLACE SUITE 201, MORRISTOWN NJ, 07960. The specialty pharmaceutical company can be reached via phone at 800-793-2145 or via email at [email protected].


This page was last updated on 10/17/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.